MetasTx LLC
MetasTx is dedicated to creating novel therapeutics to treat and prevent cancer metastasis, focusing on inhibiting PAK-1 enzyme activity to halt the spread of solid tumors such as prostate, breast, and skin cancers. Their innovative approach aims to improve patient survival and quality of life by targeting the metastatic process at its core with highly selective and stable formulations like MTX-101.
Industries
Nr. of Employees
small (1-50)
Products
MTX-101 (liposomal encapsulated allosteric PAK inhibitor)
A sterically stabilized nano‑liposomal formulation of an allosteric Group‑1 PAK inhibitor developed to increase plasma stability, extend half‑life, and concentrate drug delivery to solid tumors to inhibit metastatic processes.
IPA-3
A highly selective inhibitor of group-1 P21 activated kinases (PAKs) that inhibits metastatic movement of cancer cells and suppresses epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) to prevent metastasis.
MTX-101
A novel cancer agent with superior stability and efficacy in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer, demonstrating broad applicability across solid tumor cancers.
next-generation KIT inhibitors
A series of next-generation KIT inhibitors developed by MetasTx designed to shut down molecular signals driving cancer spread and drug resistance in prostate cancer.
MTX-101 (liposomal encapsulated allosteric PAK inhibitor)
A sterically stabilized nano‑liposomal formulation of an allosteric Group‑1 PAK inhibitor developed to increase plasma stability, extend half‑life, and concentrate drug delivery to solid tumors to inhibit metastatic processes.
IPA-3
A highly selective inhibitor of group-1 P21 activated kinases (PAKs) that inhibits metastatic movement of cancer cells and suppresses epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) to prevent metastasis.
MTX-101
A novel cancer agent with superior stability and efficacy in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer, demonstrating broad applicability across solid tumor cancers.
next-generation KIT inhibitors
A series of next-generation KIT inhibitors developed by MetasTx designed to shut down molecular signals driving cancer spread and drug resistance in prostate cancer.
Services
Design and execution of in vitro and in vivo experiments to evaluate anti‑metastatic activity of candidate compounds in tumor and bone metastasis models.
Development of sterically stabilized liposomal formulations to improve stability, half‑life, and tumor targeting of labile small molecules.
Design and execution of in vitro and in vivo experiments to evaluate anti‑metastatic activity of candidate compounds in tumor and bone metastasis models.
Development of sterically stabilized liposomal formulations to improve stability, half‑life, and tumor targeting of labile small molecules.
Expertise Areas
- Preclinical oncology drug development
- Liposomal and nanoparticle drug delivery
- Allosteric kinase inhibitor discovery
- EMT/MET biology and metastasis mechanisms
Key Technologies
- Sterically stabilized liposomes
- Nanoparticle passive tumor targeting (EPR)
- Allosteric small‑molecule kinase inhibition
- In vitro EMT/MET cellular assays